Invesaro

Stocks Comparison

Bausch & Lomb vs RxSight: revenue, profit, margins and growth compared

Bausch & Lomb brought in $5.1B of revenue in fiscal 2025, RxSight $134.5M in fiscal 2025. Revenue changed by +6.5% at Bausch & Lomb and -3.9% at RxSight on the year before, so Bausch & Lomb grew faster. Bausch & Lomb kept -7.1% of its revenue as net profit, RxSight -29.0%. Free cash flow was -$66M at Bausch & Lomb and -$19.3M at RxSight.

Side by side, latest fiscal year

BLCORXST
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$5.1B$134.5M
Revenue growth+6.5%-3.9%
Net income-$360M-$38.9M
Net margin-7.1%-29.0%
Free cash flow-$66M-$19.3M
Free cash flow margin-1.3%-14.4%
Earnings per share (diluted)-$1.02-$0.95
Cash$383M$19.9M
Debt$5Bn/a
Price to earningsn/an/a
Market value$6B$193.8M
Dividend yieldn/an/a
Rank by revenue in sector#61 of 523 · Health care#279 of 523 · Health care

Over the years

Revenue
BLCO FY2020: $3.4BBLCO FY2022: $3.8BBLCO FY2022: $3.8BBLCO FY2023: $4.1BBLCO FY2024: $4.8BBLCO FY2025: $5.1BRXST FY2021: $14.7MRXST FY2021: $22.6MRXST FY2022: $49MRXST FY2023: $89.1MRXST FY2024: $139.9MRXST FY2025: $134.5MFY20FY21FY22FY23FY24FY25
BLCO $5.1BRXST $134.5M
Net income
BLCO FY2020: -$18MBLCO FY2022: $182MBLCO FY2022: $6MBLCO FY2023: -$260MBLCO FY2024: -$317MBLCO FY2025: -$360MRXST FY2021: $27.6MRXST FY2021: -$48.7MRXST FY2022: -$66.8MRXST FY2023: -$48.6MRXST FY2024: -$27.5MRXST FY2025: -$38.9MFY20FY21FY22FY23FY24FY25
BLCO -$360MRXST -$38.9M
Net margin
BLCO FY2020: -0.5%BLCO FY2022: 4.8%BLCO FY2022: 0.2%BLCO FY2023: -6.3%BLCO FY2024: -6.6%BLCO FY2025: -7.1%RXST FY2021: 187.9%RXST FY2021: -215.5%RXST FY2022: -136.2%RXST FY2023: -54.6%RXST FY2024: -19.6%RXST FY2025: -29.0%FY20FY21FY22FY23FY24FY25
BLCO -7.1%RXST -29.0%
Revenue growth
BLCO FY2022: +10.3%BLCO FY2022: +0.1%BLCO FY2023: +10.0%BLCO FY2024: +15.6%BLCO FY2025: +6.5%RXST FY2021: +53.9%RXST FY2022: +116.9%RXST FY2023: +81.8%RXST FY2024: +57.1%RXST FY2025: -3.9%FY21FY22FY23FY24FY25
BLCO +6.5%RXST -3.9%
Free cash flow
BLCO FY2020: $269MBLCO FY2022: $680MBLCO FY2022: $170MBLCO FY2023: -$198MBLCO FY2024: -$59MBLCO FY2025: -$66MRXST FY2021: -$37.7MRXST FY2021: -$46.6MRXST FY2022: -$61.2MRXST FY2023: -$46.4MRXST FY2024: -$22.4MRXST FY2025: -$19.3MFY20FY21FY22FY23FY24FY25
BLCO -$66MRXST -$19.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about Bausch & Lomb and RxSight

Which is bigger by revenue, Bausch & Lomb or RxSight?

Bausch & Lomb is bigger by revenue: $5.1B in fiscal 2025, against $134.5M for RxSight in fiscal 2025.

Which keeps more of its revenue as profit, Bausch & Lomb or RxSight?

Bausch & Lomb had a net margin of -7.1% in fiscal 2025; RxSight had -29.0% in fiscal 2025.

Which grew revenue faster, Bausch & Lomb or RxSight?

In their latest fiscal years revenue changed by +6.5% at Bausch & Lomb and -3.9% at RxSight.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies